Martin Shkreli Walks Back Pledge To Lower Price Of Life-Saving Drug Daraprim

After facing a firestorm of criticism in September after it was revealed that Turing Pharmaceuticals AG had raised the price of Daraprim, a 62-year-old treatment for parasitic infections in cancer and HIV patients, to $750 a pill from $13.50 after acquiring it, CEO Martin Shkreli has walked back his promise to lower the price of his life-saving medication

ARSTechnica reports:

In an announcement on Tuesday, the company said that the list price of Daraprim, which jumped from $13.50 a pill to $750 a pill earlier this year, will not change. Instead, the company will offer hospitals up to 50 percent discounts and will make other adjustments to help patients afford Daraprim, a drug used to treat a parasitic infection and often given to HIV patients.

“We pledge that no patient needing Daraprim will ever be denied access,” Nancy Retzlaff, Turing’s chief commercial officer, said in a news release. She added that “drug pricing is one of the most complex parts of the healthcare industry. A drug’s list price is not the primary factor in determining patient affordability and access.”

That’s right, Turing will cut its 5000% drug price hike to just 2500% if you are a Hospital group.

The Guardian adds:

The moves are unlikely to pacify Turing’s many critics. “This cost is unjustifiable for the medically vulnerable patient population in need of this medication and unsustainable for the healthcare system,” wrote the Infectious Diseases Society of America in an open letter to Turing when the price hike was announced in September.

Toxoplasmosis, a parasitic infection, has been identified bythe Centers for Disease Control and Prevention as one of five neglected parasitic diseases for which public health action is necessary. In addition to ravaging the compromised immune systems of patients with HIV, it is also very dangerous to pregnant women and can cause miscarriage and stillbirth. The disease is often caused by undercooking meat.

Hey Martin, F U!